中国临床药理学杂志2017，Vol.33Issue(17)：1637-1640,4.DOI:10.13699/j.cnki.1001-6821.2017.17.008
二氢嘧啶脱氢酶和亚甲基四氢叶酸还原酶基因多态性与卡培他滨方案治疗结直肠癌患者药物不良反应的相关性
Relationship between dihydropyrimidine dehydrogenase and methylenetetrahydrofolate reductase gene polymorphisms and the toxicity of capecitabine-based chemotherapy in colorectal cancer patients
白羽 1吴海伟 1刘颖 1马旭 1张艳华1
作者信息
- 1. 北京大学肿瘤医院、暨北京市肿瘤防治研究所药剂科、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142
- 折叠
摘要
Abstract
Objective To analyze the distribution of dihydropyrimidine dehydrogenase (DPYD) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms of capecitabine-based regimen,and to discuss the correlations of gene polymorphisms and toxicity in colorectal cancer patients.Methods Retrospective the cancer patients from April 2015 to October 2016,who had received capecitabine-based regimen chemotherapy were included in this study.The DPYD and MTHFR genotype of 81 patients were analyzed by digital fluorescence molecular hybridization (DFMH).The adverse reactions were evaluated according to the National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI-CTCAE).Results A total of 81 colorectal cancer patients with DPYD and MTHFR genotype were analyzed.Furthermore,we do not discover the mutation of DPYD genotype in our hospital.The distribution of MTHFR genotypes were as follows:MTHFR (1298A ＞ C) wild genotype A/A of 70.37％ (57/81 cases),heterozygous mutant genotype A/C of 25.93％ (21/81 cases),and homozygous mutant genotype C/C of 3.73％ (3/81 cases).The risk of nausea and vomiting (from grade Ⅱ to grade Ⅳ) in patients carrying A/C (19.05％) and C/C (33.33％) were higher than that in wild type (1.75％,P ＜0.05).We also found that mutant genotype of MTHFR increase the risk of leukopenia and thrombocytopenia (from grade Ⅱ to grade Ⅳ),the difference was not significant (P ＞ 0.05).Conclusion There is no DPYD gene mutation in our study.Besides,MTHFR gene polymorphisms could predict capecitabine-related adverse reactions in cancer patients.关键词
二氢嘧啶脱氢酶/亚甲基四氢叶酸还原酶/基因多态性/卡培他滨/药物不良反应Key words
dihydropyrimidine dehydrogenase/methylenetetrahydrofolate reductase/polymorphism/capecitabine/adverse drug reaction分类
医药卫生引用本文复制引用
白羽,吴海伟,刘颖,马旭,张艳华..二氢嘧啶脱氢酶和亚甲基四氢叶酸还原酶基因多态性与卡培他滨方案治疗结直肠癌患者药物不良反应的相关性[J].中国临床药理学杂志,2017,33(17):1637-1640,4.
